Plain-English translation of NCT05666700 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 study testing cilta-cel, a type of immune cell therapy designed to fight myeloma that has spread outside the bone marrow and resisted previous treatments. Researchers will use special imaging technology (PET-MRI scans) to track where these cells travel in your body and how they work. A small portion of the cells will be labeled with a harmless tracer so doctors can see them on the imaging scans.
Myeloma that spreads outside the bone marrow and resists standard treatments is very difficult to treat. This study is designed to understand exactly how this new immune cell treatment moves through the body and targets cancer, which could help doctors use it more effectively in the future.
You will undergo apheresis to collect immune cells from your blood, which will then be grown in the laboratory and modified into the new treatment. Once ready, you will receive the treatment as an intravenous infusion. You will then have multiple PET-MRI imaging scans to allow doctors to track how the cells move through your body and fight the cancer. The study involves close monitoring with blood tests and imaging visits at specific timepoints to evaluate how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Peter MacCallum Cancer Centre, Australia
Collaborators
Janssen, LP
Enrollment target
~10 participants
Started
December 2023
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.